Similar articles

• Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

  Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Schrader J, et al. Stroke. 2005 Jun;36(6):1218-26. doi: 10.1161/01.STR.0000166048.35740.a9. Epub 2005 May 5. Stroke. 2005. PMID: 15879332 Clinical Trial.
• Does the MOSES trial establish superiority of AT1-receptor blockers over dihydropyridine/calcium antagonists in secondary stroke prevention?

  Fournier A, Choukroun G, Modeliar SS, Godefroy O, Achard JM, Wang J, Messerli F. Fournier A, et al. Stroke. 2006 Feb;37(2):336-7; author reply 338. doi: 10.1161/01.STR.0000199614.67737.e0. Epub 2006 Jan 5. Stroke. 2006. PMID: 16397183 Clinical Trial. No abstract available.
• Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.

  Dowlatshahi D, Hill MD. Dowlatshahi D, et al. Expert Rev Cardiovasc Ther. 2009 May;7(5):459-64. doi: 10.1586/erc.09.3. Expert Rev Cardiovasc Ther. 2009. PMID: 19419253
• Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents?

  Armario P, de la Sierra A. Armario P, et al. Ther Adv Cardiovasc Dis. 2009 Jun;3(3):197-204. doi: 10.1177/1753944709104164. Epub 2009 May 14. Ther Adv Cardiovasc Dis. 2009. PMID: 19443514 Review.
• Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?

  Rupp H. Rupp H. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S25-9. doi: 10.1185/030079907X260737. Curr Med Res Opin. 2007. PMID: 18093411 Review.